Current potential therapeutic strategies targeting the TGF-beta/Smad signaling pathway to attenuate keloid and hypertrophic scar formation.
Zhang T, Wang XF, Wang ZC, Lou D, Fang QQ, Hu YY, Zhao WY, Zhang LY, Wu LH, Tan WQ.
Biomed Pharmacother. 2020 Sep;129:110287. doi: 10.1016/j.biopha.2020.110287. Epub 2020 Jun 12.
PMID:32540643
Hypertrophic scar.
Gabriel V.
Phys Med Rehabil Clin N Am. 2011 May;22(2):301-10, vi. doi: 10.1016/j.pmr.2011.02.002.
PMID:21624722
The Most Current Algorithms for the Treatment and Prevention of Hypertrophic Scars and Keloids: A 2020 Update of the Algorithms Published 10 Years Ago.
Ogawa R.
Plast Reconstr Surg. 2022 Jan 1;149(1):79e-94e. doi: 10.1097/PRS.0000000000008667.
PMID:34813576
Exosomes derived from human adipose mesenchymal stem cells attenuate hypertrophic scar fibrosis by miR-192-5p/IL-17RA/Smad axis.
Li Y, Zhang J, Shi J, Liu K, Wang X, Jia Y, He T, Shen K, Wang Y, Liu J, Zhang W, Wang H, Zheng Z, Hu D.
Stem Cell Res Ther. 2021 Mar 31;12(1):221. doi: 10.1186/s13287-021-02290-0.
PMID:33789737
Mechanotransduction in skin wound healing and scar formation: Potential therapeutic targets for controlling hypertrophic scarring.
Yin J, Zhang S, Yang C, Wang Y, Shi B, Zheng Q, Zeng N, Huang H.
Front Immunol. 2022 Oct 17;13:1028410. doi: 10.3389/fimmu.2022.1028410. eCollection 2022.
PMID:36325354
Hypertrophic scar management.
Edwards J.
Br J Nurs. 2022 Nov 10;31(20):S24-S31. doi: 10.12968/bjon.2022.31.20.S24.